Gestational trophoblastic neoplasia: An update

Jacqueline M. Morgan, John Robert Lurain III*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors. The overall cure rate in treating these tumors currently exceeds 90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization [WHO] score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%. High-risk metastatic GTN (stage IV, WHO score ≥7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalCurrent oncology reports
Issue number6
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Gestational trophoblastic neoplasia: An update'. Together they form a unique fingerprint.

Cite this